ClinicalTrials.gg
CompletedNCT04456998Updated Nov 7, 2023Results posted

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of GB002 (seralutinib) and Placebo in Pulmonary Artery Hypertension, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.. Completed at 63 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.

02

Conditions studied

  • Pulmonary Artery Hypertension

Keywords

  • seralutinib
03

In context

Lead sponsor

GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A current diagnosis of symptomatic PAH classified by one of the following:

    1. Idiopathic PAH (IPAH) or heritable pulmonary arterial hypertension (HPAH).
    2. PAH associated with connective tissue disease (CTD-APAH).
    3. PAH associated with anorexigen or methamphetamine use.
    4. Congenital heart disease with simple systemic to pulmonary shunt at least 1 year after surgical repair.
  2. 6MWD ≥ 150 meters and ≤ 550 meters at screening.
  3. WHO FC II or III symptomatology.
  4. Treatment with standard of care PAH background therapies.
  5. Documentation of cardiac catheterization within the screening period that is consistent with the diagnosis of PAH and meeting all the following criteria, to be confirmed by a central hemodynamic core laboratory:

    1. Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg (at rest), AND
    2. PVR ≥ 400 dyne•sec/cm5, AND
    3. Pulmonary capillary wedge pressure (PCWP) or left ventricular-end diastolic pressure (LVEDP) ≤12 mm Hg if PVR ≥400 to \<500 dyne∙sec/cm5 OR
    4. PCWP or LVEDP ≤15 mmHg if PVR ≥500 dyne∙sec/cm5
  6. Pulmonary function tests (PFTs) at screening with the following criteria met:

    1. (FEV1) divided by the forced vital capacity (FVC) ≥70%;
    2. Total lung capacity (TLC) or FVC ≥ 70% predicted

Exclusion criteria

Exclusion Criteria:

  1. Evidence of chronic thromboembolic disease or acute pulmonary embolism as assessed by ventilation-perfusion (V/Q) scan, computed tomography (CT)-angiogram, or pulmonary angiogram prior to screening.
  2. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg during screening visit after a period of rest.
  3. Systolic blood pressure \< 90 mm Hg during screening and baseline visits.
  4. WHO Pulmonary Hypertension Group 2-5.
  5. (HIV)-associated PAH.
  6. History of left-sided heart disease and/or cardiac disease.
  7. Untreated severe obstructive sleep apnea.
  8. History of atrial septostomy within 180 days prior to screening.
  9. Pulmonary venous occlusive disease (PVOD).
  10. Subjects with a history of portopulmonary hypertension or portal hypertension due to cirrhosis classified as Class A or higher; or baseline or AST > 2 x or Total ≥ 2 x ULN.
  11. History of within 5 years prior to screening.
  12. History of a potentially life-threatening cardiac arrhythmia with an ongoing risk.
  13. Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or IP administration (eg; history intracranial hemorrhage).
  14. Chronic renal insufficiency as defined by an estimated (eGFR) \< 45 mL/min/1.73m2 via Chronic Kidney Disease Epidemiology Collaboration (CKD-epi) at screening or requires dialytic therapy or hemofiltration.
  15. (Hgb) concentration \< 8.5 g/dL at screening.
  16. Evidence of active HIV, or , or tuberculosis (TB) infections.
  17. Inhaled prostanoids; these drugs may be withdrawn ≥ 4 weeks prior to or at screening, if clinically indicated.
  18. Use of oral anticoagulants (ie, warfarin or NOAC) at randomization.
  19. Requirement of intravenous (IV) inotropes (ie, levosimendan, dopamine, dobutamine, milrinone, norepinephrine) other than an IV prostanoid within 4 weeks of screening.
  20. Prior participation in GB002 studies and/or prior treatment with GB002.
  21. Currently participating in or has participated in a study of an agent or has used an investigational device for the treatment of PAH within 4 weeks prior to screening.
  22. Current use of inhaled tobacco and/or inhaled marijuana.
  23. Current alcohol use disorder as defined by and/or positive test for drugs of abuse (amphetamines, methamphetamines, cocaine, phencyclidine [PCP]).
  24. Subjects with a history of severe milk protein allergy. In addition, subjects with known intolerance or to lactose who, in the opinion of the investigator, may experience severe symptoms following the ingestion of lactose.
  25. of > 480 msec recorded on a screening or baseline or receiving concurrent treatment with medications that prolong QT interval.
  26. Have any other condition or reason that, in the opinion of the Investigator or Medical Monitor, would prohibit the subject from participating in the study.

NOTE: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    GB002 (seralutinib)

    GB002 (seralutinib) inhaled orally twice per day (BID) for 24 weeks

    Drug: GB002 (seralutinib) · Device: Generic Dry Powder Inhaler

  • Placebo comparator
    Placebo

    Placebo inhaled orally BID for 24 weeks

    Drug: Placebo · Device: Generic Dry Powder Inhaler

Interventions

  • Capsule containing GB002 (seralutinib)

  • DrugPlacebo

    Matching capsule containing placebo

  • DeviceGeneric Dry Powder Inhaler

    Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR)

    PVR was evaluated using right heart catheterization (RHC).

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline to Week 24 in Distance Achieved on the Six-Minute Walk Test (6MWT)

    The 6MWT measures the distance a participant is able to walk quickly on a flat, hard surface in a period of 6 minutes.

    Time frame: Baseline, Week 24

07

Results

Posted Nov 7, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboGB002 (Seralutinib)
Started4244
Completed4238
Not completed06
Withdrew: Adverse event04
Withdrew: Protocol deviation01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR)

PVR was evaluated using right heart catheterization (RHC).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · dyne•s/cm^5
Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR)
dyne•s/cm^5PlaceboGB002 (Seralutinib)
Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR)21.2 (-37.4 to 79.8)-74.9 (-139.7 to -10.2)
Statistical analysis
  • Placebo vs GB002 (Seralutinib) · ANCOVA · p = 0.0310 · Mean difference (net): -96.1 · 95% CI -183.5 to -8.8GB002 vs. Placebo
SecondaryChange From Baseline to Week 24 in Distance Achieved on the Six-Minute Walk Test (6MWT)

The 6MWT measures the distance a participant is able to walk quickly on a flat, hard surface in a period of 6 minutes.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · meters
Change From Baseline to Week 24 in Distance Achieved on the Six-Minute Walk Test (6MWT)
metersPlaceboGB002 (Seralutinib)
Change From Baseline to Week 24 in Distance Achieved on the Six-Minute Walk Test (6MWT)7.4 (-11.2 to 25.9)13.9 (-5.1 to 32.8)
Statistical analysis
  • Placebo vs GB002 (Seralutinib) · Mixed Models Analysis · p = 0.5972 · Mean difference (net): 6.5 · 95% CI -17.9 to 30.9GB002 vs. Placebo

Adverse events

Collected over From first dose of study drug through Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/42 (0%)6/42 (14.3%)28/42 (66.7%)
GB002 (Seralutinib)0/44 (0%)10/44 (22.7%)31/44 (70.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlaceboGB002 (Seralutinib)
Right ventricular failureCardiac disorders3/421/44
HypokalaemiaMetabolism and nutrition disorders1/420/44
Pericardial effusionCardiac disorders1/420/44
Orthostatic hypotensionVascular disorders1/420/44
DyspnoeaRespiratory, thoracic and mediastinal disorders1/420/44
AppendicitisInfections and infestations0/421/44
PneumoniaInfections and infestations0/421/44
Staphylococcal bacteraemiaInfections and infestations0/421/44
Vascular device infectionInfections and infestations0/421/44
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/421/44
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlaceboGB002 (Seralutinib)
CoughRespiratory, thoracic and mediastinal disorders16/4219/44
HeadacheNervous system disorders8/426/44
COVID-19Infections and infestations7/426/44
NauseaGastrointestinal disorders6/425/44
DiarrhoeaGastrointestinal disorders3/426/44
DizzinessNervous system disorders2/425/44
FatigueGeneral disorders3/425/44
DyspnoeaRespiratory, thoracic and mediastinal disorders4/424/44
NightmarePsychiatric disorders1/424/44
Upper respiratory tract infectionInfections and infestations3/421/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboGB002 (Seralutinib)Total
Mean49.5 ± 11.8148.3 ± 12.7048.8 ± 12.22
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGB002 (Seralutinib)Total
Female384078
Male448
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGB002 (Seralutinib)Total
White373774
Black or African American101
Asian246
Other, Not Specified235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGB002 (Seralutinib)Total
Hispanic or Latino6814
Not Hispanic or Latino343670
Not Reported202
08

Study locations

63 sites
  • Pulmonary Associates, PA
    Phoenix, Arizona 85032, United States
  • Dept of Veterans Affairs Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • The University of California San Francisco
    San Francisco, California 94143, United States
  • Medical Corporation
    Santa Barbara, California 93105, United States
  • Stanford Healthcare
    Stanford, California 94305, United States
  • The Lundquist Institute of Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Central Florida Pulmonary Group, PA
    Altamonte Springs, Florida 32701, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kentuckiana Pulmonary Research Center
    Louisville, Kentucky 40202, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • New York Presbyterian Hospital - Weill Cornell Medicine
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44124, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • INTEGRIS Baptist Medical Center, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • University of Utah Health
    Salt Lake City, Utah 84132, United States
  • Medical College of Wisconsin - Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • St Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, 3065, Australia
  • Royal Hobart Hospital
    Hobart, TAS 7000, Australia
  • Westmead Hospital
    Westmead, NSW 2145, Australia
  • LKH - Univ. Klinikum Graz - Universitatsklinik fur Innere Medizin
    Graz, 8036, Austria
  • Medizinische Universitat Wien - Universitatsklinik fur Innere Medizin II
    Wien, 1090, Austria
  • Erasme University Hospital
    Bruxelles, 1070, Belgium
  • University Hospital of Leuven
    Leuven, 3000, Belgium
  • Sir Mortimer B Davis Jewish General Hospital
    Montréal, Quebec H3T 1E2, Canada
  • Peter Lougheed Centre
    Calgary, T1Y 6J4, Canada
  • London Health Sciences Centre - Victoria Hospital
    London, N6A 5W9, Canada
  • Všeobecná fakultní nemocnice v Praze
    Praha, 128 08, Czechia
  • AP-HP, Hopital de Bicetre
    Le Kremlin-Bicetre, 94270, France
  • CHU de Montpellier - Hopital Arnaud de Villeneuve
    Montpellier, 34295, France
  • Herz- und Diabeteszentrum NRW
    Bad Oeynhausen, 32545, Germany
  • DRK Kliniken Berlin - Westend
    Berlin, 14050, Germany
  • Universitätsklinikum Giessen / Marburg
    Gießen, 35392, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Zentrum fur Pulmonale Hypertonie Thoraxklinik-Heidelberg gGmbH
    Heidelberg, 69126, Germany
  • Universitatsklinikum Regensburg
    Regensburg, 93053, Germany
  • University Clinical Centre of Serbia
    Belgrade, 11000, Serbia
  • Institute for Pulmonary Diseases of Vojvodina
    Sremska Kamenica, 21204, Serbia
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
  • Royal Papworth Hospital NHS Foundation
    Cambridge, CB2 0AY, United Kingdom
  • Imperial College Healthcare NHS Trust - Hammersmith Medicines Research Limited
    London, W12 OHS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Oct 2022, 23 months.

Results were first posted in Nov 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 7, 2020
StartActual
Nov 12, 2020
Primary completionActual
Oct 17, 2022
CompletionActual
Nov 1, 2022
Results first posted
Nov 7, 2023
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04456998
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Nov 12, 2020
Primary completion
Oct 17, 2022
Completion
Nov 1, 2022
Results posted
Nov 7, 2023
Last update
Nov 7, 2023

Study contacts

Richard Aranda
study director · Gossamer Bio Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seralutinib

Start the discussion